In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investing Warburg Pincus Style

Executive Summary

Warburg Pincus' favored health care business models eliminate as much time and risk as possible from the drug discovery and development process. Competition for such investments is increasing, but Warburg reckons its size, and experience, set it apart.

You may also be interested in...



Specialty Pharma In Europe: Is Long-Term Independence Still An Option?

Current European-based specialty pharma companies are in transition, awaiting key regulatory decisions, overhauling management or engaged in M&A. Their fates will help answer a critical question: under what circumstances can this class of companies continue to deliver long term growth as independent entities?

Archimedes Raises £65 million for Leap to U.S.

About a year after Novo A/S announced the launch of its Growth Equity Fund, the firm has found a home for its first significant investment, contributing £40 million of a £65 million ($100 million) round for privately-owned UK-based specialty pharma firm Archimedes Pharma. Participants describe this as the largest private European biopharma fundraising in the last 15 years.

Ex-Shire Team Builds New Euro-Specialty Group

Archimedes joins a growing new generation of pan-European specialty pharma, highlighting the need for a single commercial partner across Europe and the increasing alternatives to big and mid-sized pharma.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV004655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel